title: Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.
abstract: Important progress has been made in the management of Helicobacter pylori infection and in this fifth edition of the Maastricht Consensus Report, key aspects related to the clinical role of H. pylori were re-evaluated in 2015. In the Maastricht V/Florence Consensus Conference, 43 experts from 24 countries examined new data related to H. pylori in five subdivided workshops: (1) Indications/Associations, (2) Diagnosis, (3) Treatment, (4) Prevention/Public Health, (5) H. pylori and the Gastric Microbiota. The results of the individual workshops were presented to a final consensus voting that included all participants. Recommendations are provided on the basis of the best available evidence and relevance to the management of H. pylori infection in the various clinical scenarios.
authors.affiliation: Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
authors.forename: P
authors.initials: P
authors.lastname: Malfertheiner
authors.affiliation: Laboratoire de Bactériologie, Inserm U853, Université de Bordeaux, Bordeaux, France.
authors.forename: F
authors.initials: F
authors.lastname: Megraud
authors.affiliation: Faculty of Health Sciences, Trinity College, Dublin, Ireland.
authors.forename: C A
authors.initials: CA
authors.lastname: O'Morain
authors.affiliation: Department of Gastroenterology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IP), Madrid, Spain.|Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
authors.forename: J P
authors.identifier: 0000-0003-2090-3445
authors.initials: JP
authors.lastname: Gisbert
authors.affiliation: Erasmus University Medical Center, Rotterdam, The Netherlands.
authors.forename: E J
authors.initials: EJ
authors.lastname: Kuipers
authors.affiliation: General Infirmary Leeds, UK.
authors.forename: A T
authors.initials: AT
authors.lastname: Axon
authors.affiliation: Internal Medicine and Gastroenterology, University of Bologna Italy, Bologna, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Bazzoli
authors.affiliation: Gastroenterology, and Liver Unit, Internal Medicine, Roma, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Gasbarrini
authors.affiliation: Nottingham, UK.
authors.forename: J
authors.initials: J
authors.lastname: Atherton
authors.affiliation: Department of Medicine (111D), Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA.
authors.forename: D Y
authors.initials: DY
authors.lastname: Graham
authors.affiliation: Department of Medicine, McMaster University, Hamilton, Canada.|Hillcroft, Beaconsfield, Buckinghamshire, UK.
authors.forename: R
authors.initials: R
authors.lastname: Hunt
authors.affiliation: Department of Gastroenterology, McMaster University, Hamilton, Canada.
authors.forename: P
authors.initials: P
authors.lastname: Moayyedi
authors.affiliation: Department of Gastroenterology, Henry Dunant Hospital, Athens, Greece.
authors.forename: T
authors.initials: T
authors.lastname: Rokkas
authors.affiliation: Department of Diagnostic Sciences, University of Padova, Padova, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Rugge
authors.affiliation: Regensburg, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Selgrad
authors.affiliation: Medizinische Hochschule Hannover, Institut für Medizinische Mikrobiologie, Hannover, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Suerbaum
authors.affiliation: Department of Medicine, Jichi Medical School, Tochigi, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Sugano
authors.affiliation: St George and Sutherland Clinical School, University of New South Wales, Sydney, Australia.
authors.forename: E M
authors.initials: EM
authors.lastname: El-Omar
mesh_terms: D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001729:Bismuth / Q000627:therapeutic use; D017291:Clarithromycin / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D004415:Dyspepsia / Q000382:microbiology; D055088:Early Detection of Cancer; D019317:Evidence-Based Medicine; D024841:Fluoroquinolones / Q000627:therapeutic use; D005756:Gastritis / Q000382:microbiology; D000069196:Gastrointestinal Microbiome; D005773:Gastroscopy; D016481:Helicobacter Infections / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy* / Q000517:prevention & control; D016480:Helicobacter pylori; D006801:Humans; D008826:Microbial Sensitivity Tests; D009593:Nitroimidazoles / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D012307:Risk Factors; D013270:Stomach / Q000382:microbiology; D013274:Stomach Neoplasms / Q000175:diagnosis* / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D009593:Nitroimidazoles; D054328:Proton Pump Inhibitors; D000658:Amoxicillin; D017291:Clarithromycin; D001729:Bismuth
keywords: GASTRITIS; HELICOBACTER PYLORI; HELICOBACTER THERAPY